Clinical Study of the Efficacy and Safety of BCD-263 and Opdivo® as Monotherapy in Subjects With Advanced Melanoma of the Skin
A phase 3 trial of Nivolumab in melanoma, run by Biocad, active and no longer recruiting.
Overview
Clinical Study of the Efficacy and Safety of BCD-263 and Opdivo® as Monotherapy in Subjects With Advanced Melanoma of the Skin is a phase 3 interventional study registered as NCT06640530 by Biocad, with 392 participants planned, started 2024-03-21 and due to reach its primary completion in 2025-12. Interventions recorded: BCD-263, Opdivo. Conditions listed: Advanced Melanoma, Melanoma (Skin). No results are recorded here; the registry entry is the source.
Setting
A Double-Blind, Randomized Clinical Study of the Efficacy and Safety of BCD-263 and Opdivo® as Monotherapy in Subjects With Advanced Melanoma of the Skin
Phase
Phase 3
Sponsor
Biocad
Registry
Enrolled
392
Similar pages
not linked directly; found by shared links- TrialA Study of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) in Patients With Resectable Stage III Skin Melanoma
- TreatmentBCD-100
- TrialEffectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma
- TrialA Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma
- TrialA Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma
- TrialMC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma
- TrialStudy Comparing Investigational Drug HBI-8000 + Nivolumab vs. Placebo + Nivolumab in Patients With Advanced Melanoma
- TrialA Study of TRK-950 in Patients With Advanced Solid Tumors